---
layout: default
title: Vinorelbine
description: "Vinorelbine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 191
evidence_level: L1
indication_count: 10
---

# Vinorelbine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Vinorelbineï¼šå¾éå°ç´°èƒè‚ºç™Œåˆ° Ewing è‚‰ç˜¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Vinorelbine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Vinorelbine åŸæœ¬ç”¨æ–¼æ²»ç™‚éå°ç´°èƒè‚ºç™Œå’Œè½‰ç§»æ€§ä¹³ç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å° **Ewing è‚‰ç˜¤ (Ewing sarcoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **4 å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | Ewing sarcomaã€fibromatosis, gingivalã€fibroma of lungã€lung germ cell tumorã€pulmonary sulcus neoplasmã€hamartoma of lungã€small cell lung carcinomaã€lung cancerã€lung benign neoplasmã€lung hilum carcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.999% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 19 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. Ewing sarcoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Vinorelbine æ˜¯åŠåˆæˆçš„é•·æ˜¥èŠ±ç”Ÿç‰©é¹¼ï¼ˆVinca alkaloidï¼‰ï¼Œé€éé˜»æ–·å¾®ç®¡è›‹ç™½èšåˆæŠ‘åˆ¶æœ‰çµ²åˆ†è£‚ã€‚Ewing è‚‰ç˜¤æ˜¯ä¸€ç¨®é«˜åº¦å¢æ®–çš„æƒ¡æ€§è…«ç˜¤ï¼Œå°å¾®ç®¡æŠ‘åˆ¶åŠ‘å…·æœ‰æ•æ„Ÿæ€§ã€‚Vinorelbine åœ¨å¤šé …å…’ç«¥é›£æ²»æ€§è…«ç˜¤çš„è‡¨åºŠè©¦é©—ä¸­å±•ç¾æ´»æ€§ï¼ŒåŒ…æ‹¬ Ewing è‚‰ç˜¤ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT06451302">NCT06451302</a></td>
<td>N/A</td>
<td>ACTIVE_NOT_RECRUITING</td>
<td>100</td>
<td>è©•ä¼°ä¸­åœ‹å…’ç«¥ Ewing è‚‰ç˜¤é¢¨éšªåˆ†å±¤å°å‘æ²»ç™‚çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00003234">NCT00003234</a></td>
<td>Phase 2</td>
<td>COMPLETED</td>
<td>50</td>
<td>ç ”ç©¶ Vinorelbine åœ¨å¾©ç™¼/é›£æ²»æ€§å…’ç«¥æƒ¡æ€§è…«ç˜¤ä¸­çš„æ•ˆæœï¼ŒåŒ…æ‹¬ Ewing è‚‰ç˜¤</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00180947">NCT00180947</a></td>
<td>Phase 2</td>
<td>UNKNOWN</td>
<td>210</td>
<td>è©•ä¼° Vinorelbine èˆ‡ Cyclophosphamide çµ„åˆåœ¨é›£æ²»æ€§è…«ç˜¤ä¸­çš„æŠ—è…«ç˜¤æ´»æ€§</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT05999994">NCT05999994</a></td>
<td>Phase 2</td>
<td>RECRUITING</td>
<td>105</td>
<td>CAMPFIRE å…’ç«¥å’Œé’å°‘å¹´å‰µæ–°ç ”ç©¶ä¸»å”è­°</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>ç›®å‰ç„¡å°ˆé–€é‡å° Vinorelbine ç”¨æ–¼ Ewing è‚‰ç˜¤çš„ PubMed æ–‡ç»æ”¶éŒ„ï¼Œä½†æœ‰ç›¸é—œçš„å…’ç§‘è…«ç˜¤ç ”ç©¶æ–‡ç»æ”¯æŒå…¶åœ¨é›£æ²»æ€§è‚‰ç˜¤ä¸­çš„æ‡‰ç”¨ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. fibromatosis, gingival</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. fibroma of lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. lung germ cell tumor</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ3 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02489903" target="_blank">NCT02489903</a></td><td>PHASE2</td><td>COMPLETED</td><td>139</td><td>A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinom...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03951142" target="_blank">NCT03951142</a></td><td>PHASE2</td><td>UNKNOWN</td><td>165</td><td>Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label L...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01155258" target="_blank">NCT01155258</a></td><td>PHASE1</td><td>COMPLETED</td><td>19</td><td>Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ13 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30025492/" target="_blank">30025492</a></td><td>2018</td><td>Article</td><td>Journal of chemother</td><td>Vinorelbine&#x27;s anti-tumor actions may depend on the mitotic a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37458143/" target="_blank">37458143</a></td><td>2024</td><td>Article</td><td>Fundamental &amp; clinic</td><td>Dose-dependent bidirectional pharmacological effects of vino...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19699548/" target="_blank">19699548</a></td><td>2010</td><td>Article</td><td>Lung cancer (Amsterd</td><td>Comparison of chemotherapy for unresectable pulmonary high-g...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28572122/" target="_blank">28572122</a></td><td>2017</td><td>Article</td><td>The European respira</td><td>Chemotherapy for pulmonary large cell neuroendocrine carcino...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33525370/" target="_blank">33525370</a></td><td>2021</td><td>Article</td><td>Medicina (Kaunas, Li</td><td>Outcomes of Patients with Pulmonary Large Cell Neuroendocrin...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 8 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. pulmonary sulcus neoplasm</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ4 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26730751/" target="_blank">26730751</a></td><td>2015</td><td>Article</td><td>Chinese clinical onc</td><td>Combined treatment modalities in Pancoast tumor: results of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25886271/" target="_blank">25886271</a></td><td>2015</td><td>Article</td><td>BMC cancer</td><td>Ion therapy within the trimodal management of superior sulcu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30689794/" target="_blank">30689794</a></td><td>2019</td><td>Article</td><td>European journal of </td><td>Trimodality therapy for superior sulcus tumour: experience o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31664634/" target="_blank">31664634</a></td><td>2019</td><td>Article</td><td>Surgical case report</td><td>Adenocarcinoma with fetal features invading the right superi...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hamartoma of lung</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15143989/" target="_blank">15143989</a></td><td>2004</td><td>Article</td><td>Tumori</td><td>Spontaneous splenic rupture after the start of lung cancer c...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. small cell lung carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03652857" target="_blank">NCT03652857</a></td><td>PHASE2</td><td>COMPLETED</td><td>30</td><td>the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used fo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00004093" target="_blank">NCT00004093</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>36</td><td>A Phase I-II Study of Induction Chemotherapy With Carboplatin and Gemcitabine, F...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02176369" target="_blank">NCT02176369</a></td><td>PHASE2</td><td>COMPLETED</td><td>120</td><td>Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previou...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01203735" target="_blank">NCT01203735</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>20</td><td>Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Vinorelbine...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04648033" target="_blank">NCT04648033</a></td><td>PHASE1</td><td>COMPLETED</td><td>21</td><td>A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination With Radical C...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32407216/" target="_blank">32407216</a></td><td>2020</td><td>Article</td><td>Journal of clinical </td><td>Randomized Phase III Study of Pemetrexed Plus Cisplatin Vers...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16945766/" target="_blank">16945766</a></td><td>2006</td><td>Article</td><td>The Lancet. Oncology</td><td>Adjuvant vinorelbine plus cisplatin versus observation in pa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31935454/" target="_blank">31935454</a></td><td>2020</td><td>Article</td><td>Pharmacological rese</td><td>Clinical efficacy and safety of aidi injection combination w...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36027483/" target="_blank">36027483</a></td><td>2022</td><td>Article</td><td>Journal of clinical </td><td>Updated Overall Survival and Exploratory Analysis From Rando...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31262897/" target="_blank">31262897</a></td><td>2019</td><td>Article</td><td>Anticancer research</td><td>Cisplatin and Vinorelbine -Mediated Electrochemotherapeutic ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. lung benign neoplasm</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16945766/" target="_blank">16945766</a></td><td>2006</td><td>Article</td><td>The Lancet. Oncology</td><td>Adjuvant vinorelbine plus cisplatin versus observation in pa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25750330/" target="_blank">25750330</a></td><td>2015</td><td>Article</td><td>Anticancer research</td><td>Vinorelbine and cisplatin in patients with advanced non-smal...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11325488/" target="_blank">11325488</a></td><td>2001</td><td>Article</td><td>Lung cancer (Amsterd</td><td>Carboplatin and vinorelbine in untreated locally advanced an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12454762/" target="_blank">12454762</a></td><td>2002</td><td>Article</td><td>British journal of c</td><td>Triplet chemotherapy with vinorelbine, gemcitabine, and cisp...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32416433/" target="_blank">32416433</a></td><td>2020</td><td>Article</td><td>Lung cancer (Amsterd</td><td>Metronomic oral vinorelbine and lung cancer therapy during t...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. lung hilum carcinoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21677493/" target="_blank">21677493</a></td><td>2011</td><td>Article</td><td>Gan to kagaku ryoho.</td><td>[A radical resection of non-small cell lung cancer invading ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. pulmonary blastoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30106243/" target="_blank">30106243</a></td><td>2018</td><td>Article</td><td>Thoracic cancer</td><td>Blastomatoid pulmonary carcinosarcoma: A rare case report an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12088262/" target="_blank">12088262</a></td><td>2002</td><td>Article</td><td>Tumori</td><td>Pulmonary blastoma after liver transplant: a case report.</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬022215è™Ÿ | æº«è«¾å¹³æ³¨å°„æ¶²10å…¬çµ²/å…¬æ’® | æ³¨å°„åŠ‘ | éå°ç´°èƒè‚ºç™Œï¼Œè½‰ç§»æ€§ä¹³ç™Œ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024268è™Ÿ | æº«è«¾å¹³30æ¯«å…‹è»Ÿè† å›Š | è»Ÿè† å›ŠåŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024269è™Ÿ | æº«è«¾å¹³20æ¯«å…‹è»Ÿè† å›Š | è»Ÿè† å›ŠåŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬060608è™Ÿ | å¨è‹¥è³“30æ¯«å…‹è»Ÿè† å›Š | è»Ÿè† å›ŠåŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬025489è™Ÿ | ç¶­è«¾æ‹œæ³¨å°„æ¶² | æ³¨å°„åŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰©ï¼ˆVinca alkaloidï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ï¼ˆå—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ç‚ºåŠ‘é‡é™åˆ¶æ¯’æ€§ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚åŠŸèƒ½ã€ç¥ç¶“æ¯’æ€§è©•ä¼° |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œï¼›éœè„ˆæ³¨å°„éœ€æ³¨æ„å¤–æ»²é¢¨éšª |

## å®‰å…¨æ€§è€ƒé‡

### é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆMajorï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰èªªæ˜ |
|-------------|---------|
| Clarithromycin | CYP3A4 æŠ‘åˆ¶åŠ‘ï¼Œå¢åŠ  vinorelbine è¡€ä¸­æ¿ƒåº¦å’Œæ¯’æ€§ |

### ä¸­åº¦è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆModerateï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰èªªæ˜ |
|-------------|---------|
| Aprepitant | CYP3A4 æŠ‘åˆ¶ |
| Dexamethasone | å¯èƒ½å½±éŸ¿ä»£è¬ |
| Simvastatin | CYP3A4 ç«¶çˆ­ |
| Rosuvastatin | è—¥ç‰©è½‰é‹é«”äº¤äº’ä½œç”¨ |

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCYP3A4 ä»£è¬è—¥ç‰©ï¼Œè‘¡è„æŸšå¯èƒ½å½±éŸ¿ä»£è¬
- å»ºè­°ï¼šåŒ–ç™‚æœŸé–“é¿å…è‘¡è„æŸš


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Gastrointestinal Diseases** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Neuromuscular Diseases** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Respiratory Insufficiency** ğŸŸ¢ Minor
- å¯èƒ½å±åŠç”Ÿå‘½ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šVinorelbine is extensively metabolized by the liver...

**Infections** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€æ„ŸæŸ“ã€è¡€æ “ã€è²§è¡€ã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€æ„ŸæŸ“ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Vinorelbine åœ¨å¤šé …å…’ç«¥è…«ç˜¤è‡¨åºŠè©¦é©—ä¸­é¡¯ç¤ºå° Ewing è‚‰ç˜¤å…·æœ‰æ½›åœ¨ç™‚æ•ˆï¼Œä¸”ä½œç”¨æ©Ÿè½‰ï¼ˆå¾®ç®¡æŠ‘åˆ¶ï¼‰å°é«˜å¢æ®–æ€§è…«ç˜¤å…·æœ‰åˆç†çš„ç”Ÿç‰©å­¸åŸºç¤ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ”¶é›†å°ˆé–€é‡å° Ewing è‚‰ç˜¤çš„ç™‚æ•ˆæ•¸æ“š
- ç¢ºå®šé©ç•¶çš„å…’ç§‘åŠ‘é‡å’Œçµ¦è—¥æ–¹æ¡ˆ
- èˆ‡ç¾æœ‰ Ewing è‚‰ç˜¤æ¨™æº–æ²»ç™‚æ–¹æ¡ˆçš„æ¯”è¼ƒè©•ä¼°
- éª¨é«“æŠ‘åˆ¶å’Œç¥ç¶“æ¯’æ€§çš„å¯†åˆ‡ç›£æ¸¬è¨ˆç•«

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dorzolamide]({{ "/drugs/dorzolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Prednisolone]({{ "/drugs/prednisolone/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Vinorelbineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/vinorelbine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_vinorelbine,
  title = {Vinorelbineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/vinorelbine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
